AngioSoma, Inc. (OTCMKTS:SOAN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
AngioSoma, Inc. (the “Company”) has dissolved all relationships with David P. Summers, PhD, and has terminated his positions as Chairman Emeritus and consultant, as well as any and all written or oral agreements and understandings.
Section 7 – Regulation FD
ITEM 7.01 Regulation FD Disclosure.
The Company is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, LiprostinTM, through the FDA approval process. The regulatory firm will begin with a presubmission meeting with the FDA biologic group to obtain a regulatory strategy consensus with the FDA for authority to proceed. The objective is agreement for the protocol for the third and final clinical trial.
Section 9 – Financial Statements and Exhibits
ITEM 9.01 Financial Statements and Exhibits.
|
EXHIBIT NO. |
DESCRIPTION |
|
Exhibit 99.1 |
Press release issued June 18, 2018 |
AngioSoma, Inc. ExhibitEX-99 2 ex_99-1.htm PRESS RELEASE ISSUED JUNE 18,…To view the full exhibit click here
